FICHIT

Je m'inscris

NEOVACS

0/5 (0 note(s))
Note donnée : aucune
Paris
36
R&D in immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.
The IFN?-Kinoïd is an anti interferon alpha (IFN?) therapeutic vaccine developed for the treatment of lupus (or Systemic Lupus Erythematosus, SLE). Neovacs has shown that the self antibodies produced by administration of the IFN?-Kinoïd neutralize all 13 sub-types of IFN? in the serum of lupus patients. This breadth of activity supports the positioning of Neovacs’ therapeutic vaccine as a next-generation treatment for this disease. A phase I/II clinical trial of IFN?-Kinoïd in lupus patient was conducted in 2010-2011. Very promising final results of the study were presented during the American College for Rheumatology Annual Meeting-Chicago in 2011 and published in 2013 in Arthritis & Rheumatology.
TNF-Kinoid is an anti-TNF immunotherapy originating from Neovacs Kinoid technology. A phase IIb clinical trial of TNF-Kinoid in rheumatoid arthritis was initiated mid-2013. Results have been published at the end of 2014.
TREPO Nathalie
www.neovacs.fr
ALNEV:FP

Fiche créée le 10/04/2016 par Guillaume   vue 7 fois.